A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis (A Randomized, Double-blind, Placebo-controlled Study).

Trial Profile

A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis (A Randomized, Double-blind, Placebo-controlled Study).

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2015

At a glance

  • Drugs Bepotastine (Primary)
  • Indications Perennial allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 26 May 2015 Mitsubishi Tanabe received approval for bepotastine [Talion and Talion OD tablets] for additional pediatric allergic diseases (for children at least seven years of age) in Japan. This approval was based on efficacy and safety results from trials conducted in pediatric patients in Japan.
    • 21 Mar 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 21 Mar 2012 Actual patient number is 490 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top